Recruiting

Investigating a treatment for moderate-to-severe active thyroid eye disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of subcutaneous teprotumumab in participants with moderate-to-severe active thyroid eye disease (TED). TED is an autoimmune disease in which the eye muscles and fatty tissue behind the eye become inflamed. This can push the eyes forward (bulging) or cause redness and swelling. Symptoms can range from mild to sight-threatening. Current treatment options for moderate/severe TED are not optimal (lots of side effects), but teprotumumab holds promise and is being tested for treatment of TED in this trial.

Status
Recruiting

Testing a gene therapy to treat wet age-related macular degeneration

The purpose of this study is to investigate NG101 AAV gene therapy in adults with wet age-related macular degeneration. NG101 is being developed as a novel one-time gene therapy for the treatment of wet AMD, a significant cause of vision loss in patients worldwide. Current standard of care therapies require life-long intraocular injections (typically repeated every four to 12 weeks) to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time.

Status
Recruiting

Evaluating the safety and performance of the CorNeat KPro for corneal blindness

The purpose of this study is to evaluate the clinical safety and performance of the CorNeat Keratoprosthesis (KPro). The CorNeat KPro is a synthetic cornea developed to provide a long-lasting medical solution for corneal blindness, pathology and injury. The solution is designed to provide an accessible, efficient, effective and reliable remedy for people with cornea-related visual impairments.

Eligible participants will undergo a procedure to implant the keratoprosthesis. Following this, a total of 16 follow-up visits would be scheduled post operation. 

Status
Recruiting

Evaluating the efficacy of a gene therapy to treat vision loss

The purpose of this study is to evaluate the efficacy and safety of a novel gene therapy in participants with wet age-related macular degeneration (nAMD), a significant cause of vision loss for people worldwide. Current standard of care therapies require life-long intraocular injections that are typically repeated every 4-12 weeks to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. As such, gene therapy RGX-314 is being developed as a potential one-time treatment for nAMD.

Status
Recruiting

Automated detection of autonomic dysreflexia via deep learning

The purpose of this study is to investigate if and how retinal blood vessels change after a spinal cord injury (SCI) and the associations of these changes with cardiovascular diseases. Using images of retinal blood vessels, we will develop a deep learning-based screening tool for autonomic dysreflexia, a cardiovascular complication unique to SCI.

Recruitment Poster

Status
Recruiting

Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease (CRISEPTED)

Thyroid eye disease is an autoimmune disorder affecting approximately 50% of individuals with autoimmune thyroid diseases resulting in enlargement of ocular muscles and may lead to congestion of the eyelids and ocular surface, ocular movement restriction and double vision, and optic nerve compression and loss of vision.

First line medical therapy is oral or intravenous corticosteroids (CS), which several studies have shown results in reduction of soft tissue congestion, but some studies suggesting that ocular restriction or visual loss may still occur in spite of CS therapy.

Status
Recruiting

Closed for Recruitment

Evaluating a drug treatment for severe thyroid eye disease

The purpose of this study is to evaluate the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily versus placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease.

Status
Closed for Recruitment

Study of Ataluren in Patients With Aniridia (STAR)

This is a Phase 2, randomized, double-masked, placebo-controlled study of ataluren in patients with aniridia caused by a nonsense mutation. Patients will receive masked study drug for 48 weeks followed by open-label ataluren for another 48 weeks. Safety and efficacy will be assessed.

Status
Closed for Recruitment

Efficacy and Safety of RTH258 Versus Aflibercept

The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Status
Closed for Recruitment

Efficacy and Safety of RTH258 Versus Aflibercept

The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Status
Closed for Recruitment

Treatment for CI-DME in Eyes With Very Good VA Study (Protocol V)

Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes with poor visual acuity, such as a visual acuity letter score of 78 or worse (approximate Snellen equivalent of 20/32 or worse) were eligible. Eyes that have central-involved DME with "good" visual acuity (20/25 or better) have not been addressed systematically by recent studies for treatment of DME.

Status
Closed for Recruitment

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis (VISUAL III)

There is an unmet medical need in non-infectious intermediate-, posterior- and pan uveitis. These types of uveitis are at a higher risk for vision loss compared to anterior uveitis. Patients with these types of uveitis are often treated with chronic corticosteroids. The use of chronic corticosteroids is linked with predictable long-term side effects. The objective of this study is to evaluate the long term efficacy and safety of adalimumab subjects with non-infectious intermediate-, posterior- or pan-uveitis.

Status
Closed for Recruitment
Principal Investigator
Patrick Ma
Body Locations and Systems
Uveitis
Area
Vancouver
Age
18-99
Subscribe to Eyes and Vision